Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A‐Y93
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Medical Virology"
DOI: 10.1002/jmv.24978
Abstract: In this study, we investigated the real‐world data of the first approved interferon‐free regimen in Japan, daclatasvir and asunaprevir (DCV+ASV), in chronic hepatitis C patients infected HCV genotype 1b with no or subtle amount of… read more here.
Keywords: resistant associated; treatment; daclatasvir asunaprevir; associated substitutions ... See more keywords
Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
Sign Up to like & getrecommendations! Published in 2017 at "Value in health regional issues"
DOI: 10.1016/j.vhri.2016.10.002
Abstract: BACKGROUND The advent of highly efficacious, well-tolerated, all-oral direct-acting antiviral regimens has revolutionized the standard of care for patients chronically infected with hepatitis C virus. As efficacy and safety rates converge, prescribers and payers need… read more here.
Keywords: sofosbuvir ledipasvir; budget impact; treatment; daclatasvir asunaprevir ... See more keywords
HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0187409
Abstract: Background & aims High cure rates are achieved in HCV genotype-1b patients treated with daclatasvir and asunaprevir, DCV/ASV. Here we analyzed early HCV kinetics in genotype-1b infected Japanese subjects treated with DCV/ASV and retrospectively projected,… read more here.
Keywords: dcv asv; hcv; modeling; daclatasvir asunaprevir ... See more keywords